Third Wave to Submit HPV Study Results to FDA in April; Shares Jump

Mar 12, 2008

NEW YORK (GenomeWeb News) – Third Wave Technologies said yesterday after the close of the market that it will submit data from clinical trials on its human papillomavirus molecular diagnostic tests with the US Food and Drug Administration next month.

Investors responded enthusiastically to the news, sending Third Wave's shares up 33 percent to $9.45 in early Wednesday trade on the Nasdaq.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Years and Years

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Diving Evolution

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

This Week in Science

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

Issues to Overcome

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

Main menu